{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable&page=3",
    "query": {
      "intervention": "Injectable",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 14387,
    "total_pages": 1439,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T02:07:28.290Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04225273",
      "title": "Extension Study for 43USSA1705",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Nasolabial Folds"
      ],
      "interventions": [
        {
          "name": "Sculptra Aesthetic, Lidocaine HCL",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2019-12-03",
      "completion_date": "2021-01-29",
      "has_results": true,
      "last_update_posted_date": "2025-03-12",
      "last_synced_at": "2026-10-21T02:07:28.290Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Bradenton, Florida • Austin, Texas + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Spring",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04225273"
    },
    {
      "nct_id": "NCT06081283",
      "title": "Antiseizure Medication in Seizure Networks at Early Acute Brain Injury",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Brain Injuries, Acute",
        "Brain Injuries, Traumatic",
        "Brain Ischemia",
        "Brain Hypoxia",
        "Hypoxia-Ischemia, Brain",
        "Heart Arrest",
        "Stroke",
        "Intracranial Hemorrhages",
        "Coma",
        "Persistent Vegetative State"
      ],
      "interventions": [
        {
          "name": "Phenobarbital Sodium Injection",
          "type": "DRUG"
        },
        {
          "name": "Levetiracetam",
          "type": "DRUG"
        },
        {
          "name": "Lacosamide Injectable Product",
          "type": "DRUG"
        },
        {
          "name": "Valproate Sodium",
          "type": "DRUG"
        },
        {
          "name": "Fosphenytoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Months to 70 Years"
      },
      "enrollment_count": 5,
      "start_date": "2023-11-20",
      "completion_date": "2025-01-22",
      "has_results": true,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-10-21T02:07:28.290Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06081283"
    },
    {
      "nct_id": "NCT03417245",
      "title": "A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "fitusiran",
          "type": "DRUG"
        },
        {
          "name": "factor concentrates",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 120,
      "start_date": "2018-03-01",
      "completion_date": "2021-07-14",
      "has_results": true,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-10-21T02:07:28.290Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • Gainesville, Florida • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03417245"
    },
    {
      "nct_id": "NCT03792477",
      "title": "A Bioequivalence Study of Testosterone Cypionate in Hypogonadal Males",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypogonadism"
      ],
      "interventions": [
        {
          "name": "Test formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Reference formulation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 74,
      "start_date": "2019-01-19",
      "completion_date": "2020-04-02",
      "has_results": true,
      "last_update_posted_date": "2021-04-29",
      "last_synced_at": "2026-10-21T02:07:28.290Z",
      "location_count": 2,
      "location_summary": "DeLand, Florida • Miami, Florida",
      "locations": [
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03792477"
    },
    {
      "nct_id": "NCT07469501",
      "title": "Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Opioid Use Disorder",
        "Fentanyl"
      ],
      "interventions": [
        {
          "name": "Injectable buprenorphine",
          "type": "DRUG"
        },
        {
          "name": "Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-06",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-10-21T02:07:28.290Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07469501"
    },
    {
      "nct_id": "NCT04518228",
      "title": "Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV",
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Bictegravir (BIC)",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir alafenamide (TAF)",
          "type": "DRUG"
        },
        {
          "name": "Long-acting injectable formulation of cabotegravir (CAB LA)",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir (DTG)",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir/ritonavir (ATV/r)",
          "type": "DRUG"
        },
        {
          "name": "Darunavir/ritonavir (DRV/r)",
          "type": "DRUG"
        },
        {
          "name": "Lopinavir/ritonavir (LPV/r)",
          "type": "DRUG"
        },
        {
          "name": "Cobicistat",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "First-Line TB Treatment",
          "type": "DRUG"
        },
        {
          "name": "Second-Line TB Treatment",
          "type": "DRUG"
        },
        {
          "name": "Doravirine (DOR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 205,
      "start_date": "2021-09-01",
      "completion_date": "2025-07-10",
      "has_results": true,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-10-21T02:07:28.290Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04518228"
    },
    {
      "nct_id": "NCT00000400",
      "title": "Alendronate and/or Parathyroid Hormone for Osteoporosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Human parathyroid hormone [hPTH-(1-34)]",
          "type": "DRUG"
        },
        {
          "name": "alendronate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "45 Years to 85 Years"
      },
      "enrollment_count": 176,
      "start_date": "1999-08",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2013-12-09",
      "last_synced_at": "2026-10-21T02:07:28.290Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000400"
    },
    {
      "nct_id": "NCT03546907",
      "title": "Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "SAR440340",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Any Inhaled Corticosteroids as prescribed by treating physician as standard of care",
          "type": "DRUG"
        },
        {
          "name": "Any Long Acting Beta Agonist as prescribed by treating physician as standard of care",
          "type": "DRUG"
        },
        {
          "name": "Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care",
          "type": "DRUG"
        },
        {
          "name": "Any short-acting β agonist as prescribed by treating physician as standard of care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 343,
      "start_date": "2018-07-16",
      "completion_date": "2020-02-21",
      "has_results": true,
      "last_update_posted_date": "2022-11-22",
      "last_synced_at": "2026-10-21T02:07:28.290Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Riverside, California • Rolling Hills Estates, California + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Westminster",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03546907"
    },
    {
      "nct_id": "NCT05820711",
      "title": "Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Xerostomia"
      ],
      "interventions": [
        {
          "name": "MSC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 23,
      "start_date": "2023-07-17",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-10-21T02:07:28.290Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05820711"
    },
    {
      "nct_id": "NCT02756364",
      "title": "Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Sapanisertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 141,
      "start_date": "2016-07-28",
      "completion_date": "2019-11-25",
      "has_results": true,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-10-21T02:07:28.290Z",
      "location_count": 30,
      "location_summary": "Mobile, Alabama • Bakersfield, California • Fullerton, California + 26 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02756364"
    }
  ]
}